Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

13,646 results
MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 3
1965 1
1973 1
1989 6
1992 2
1993 2
1994 13
1995 177
1996 510
1997 494
1998 523
1999 474
2000 584
2001 535
2002 504
2003 641
2004 653
2005 680
2006 653
2007 665
2008 731
2009 675
2010 672
2011 679
2012 726
2013 833
2014 728
2015 785
2016 627
2017 584
2018 563
2019 209
Text availability
Article attribute
Article type
Publication date

Search Results

13,646 results
Results by year
Filters applied: . Clear all
Page 1
Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success
Cazzaniga ME, et al. Breast Cancer Res Treat 2019 - Review. PMID 31065872 Free PMC article.
PURPOSE: Agents targeting HR-positive, HER2-negative locally advanced or metastatic breast cancer have improved patient outcomes compared with conventional single-agent endocrine therapy. Currently, approved targeted agents include everolimus and three CDK4/6 inhibitors, palbociclib, ribociclib, and abemaciclib. ...
PURPOSE: Agents targeting HR-positive, HER2-negative locally advanced or metastatic breast cancer have improved patient outcomes compared with conventional single-agent endocrine therapy. Currently, approved targeted agents include everolimus and three CDK4/6 inhibitors, palbociclib, r …
Chemotherapy for breast cancer (Review)
Hassan MS, et al. Oncol Rep 2010 - Review. PMID 20878101
The use of cytotoxic chemotherapy in both advanced and early stage breast cancer has made significant progress in the last 10 years with several landmark studies identifying clear survival benefits for newer therapies. ...Increased improvements in the use of a panel of biomarkers will thus not only move us towards tailored therapies but will also spare a group of patients that do not benefit from adjuvant chemotherapy. ...
The use of cytotoxic chemotherapy in both advanced and early stage breast cancer has made significant progress in the last 10 years with several landmark studies identifying clear survival benefits for newer therapies. ...Increased improvements in the use of a panel of biomarkers will …
Tamoxifen and pregnancy: an absolute contraindication?
Schuurman TN, et al. Breast Cancer Res Treat 2019 - Review. PMID 30707336
However, the use of tamoxifen is considered contraindicated during pregnancy, because of a limited number of case reports demonstrating potential adverse effects on the fetus. ...Patients should be counseled about the use of tamoxifen during pregnancy instead of presenting it as being absolutely contraindicated....
However, the use of tamoxifen is considered contraindicated during pregnancy, because of a limited number of case reports demonstrating potential adverse effects on the fetus. ...Patients should be counseled about the use of tamoxifen during pregnancy instead of presenting it as being …
Androgen Deprivation Therapy for Prostate Cancer
Pagliarulo V. Adv Exp Med Biol 2018 - Review. PMID 30324345
Nonetheless, the use of androgen deprivation therapy (ADT) has increased over the years, suggesting that patients in Europe and United States may receive ADT in cases of lower disease burden, and not always according to evidence based indications. ...Thus, there is a need for more effective, specific and well tolerated agents which can provide a longer and good quality of life while avoiding the side effects related to disease and treatment morbidity.After mentioning the current knowledge on the endocrinology of androgens and androgen receptor, relevant to PC development, as well as the possible events occurring during PC initiation, we will compare different hormonal compounds available for the treatment of PC, both from a pharmacological standpoint, and in terms of contemporary clinical indications....
Nonetheless, the use of androgen deprivation therapy (ADT) has increased over the years, suggesting that patients in Europe and United States may receive ADT in cases of lower disease burden, and not always according to evidence based indications. ...Thus, there is a need for more effective, …
Endocrine therapy for breast cancer in the primary care setting
Awan A and Esfahani K. Curr Oncol 2018. PMID 30111969 Free PMC article.
The primary care physician will thus play an increasing role in the routine care, surveillance, and treatment of issues associated with anti-hormonal therapy. ...KEY POINTS: ■ Hormone-positive bca is the most prevalent form of bca and, compared with the other subtypes, is usually associated with better survival.■ Survivorship has significantly increased for all stages of hormone-positive bca, making the primary care physician a key player in the care of affected patients.■ The two most common classes of anti-hormonal agents used in these patients are selective estrogen receptor modulators and aromatase inhibitors. ...
The primary care physician will thus play an increasing role in the routine care, surveillance, and treatment of issues associated with anti-hormonal therapy. ...KEY POINTS: ■ Hormone-positive bca is the most prevalent form of bca and, compared with the other subtypes, is usually associated w …
13,646 results
Jump to page
Feedback